Crescent Biopharma, Inc. (CBIO) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Waltham, MA, アメリカ. 現CEOは Joshua T. Brumm.
CBIO を有する IPO日 2014-01-10, 41 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $537.91M.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics, including novel combinations. The company is headquartered in Waltham, Massachusetts.
